Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSearching for how to mix 10mg semaglutide points to a decision worth pausing on. There is no licensed UK weight-loss medicine containing 10mg semaglutide as a powder to be reconstituted: Wegovy, the only semaglutide product licensed in the UK for weight management, comes as a pre-filled, ready-to-inject pen — no mixing, no vials, no bacteriostatic water. The 10mg semaglutide you are reading about is almost certainly a research peptide or a compounded product, neither of which holds a UK medicines licence for human weight management. Understanding that distinction is not a technicality; it shapes every practical question that follows, from safety and storage to what a legitimate prescription actually involves. The NHS tirzepatide guidance and the NHS semaglutide medicines page both describe only ready-to-use licensed formulations, there is no NHS or MHRA-endorsed reconstitution protocol for weight-loss semaglutide in the UK.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide is a peptide hormone. In pharmaceutical manufacturing, peptide drugs are often synthesised and sold as lyophilised (freeze-dried) powders before being formulated into final products. Research-grade semaglutide in powder form is manufactured for laboratory and pre-clinical use, not for human injection. It reaches consumers (typically through grey-market peptide suppliers) outside any regulated supply chain.
The practical result is that when someone asks how to mix semaglutide 10mg, they are usually describing a process of dissolving this powder in bacteriostatic water (water preserved with benzyl alcohol) to produce an injectable solution at a chosen concentration. Suppliers often suggest specific ratios and dosing volumes. None of that guidance carries regulatory approval. The powder's actual peptide content, sterility, and purity have not been verified by the MHRA or any equivalent body. Two vials from the same supplier can contain different amounts of active compound.
For context on scale: the MHRA's enforcement work through 2024 and 2025 led to the seizure of approximately 20 million doses of illegally traded weight-loss medicines worth around £45 million, including a raid on a site in Northampton producing counterfeit tirzepatide pens. The fake-medicine problem is not abstract. You can report suspect sellers at the MHRA's Yellow Card portal.
None of this means the question is unreasonable to ask. People searching for how to mix 10mg semaglutide are usually people who want to lose weight, have seen the prices of licensed products, and found what appears to be a cheaper route. That logic is worth examining directly.
Even if a powder were pharmaceutical-grade (which cannot be confirmed without independent assay) reconstituting an injectable at home introduces its own hazards. Sterility is the first. A licensed pre-filled pen is manufactured under strict aseptic conditions and sealed. Once you introduce bacteriostatic water to a vial using a syringe and needle, the window for contamination opens. Bacterial infection at an injection site can range from a localised abscess to septicaemia.
Concentration accuracy is the second. If you dissolve 10mg of powder in, say, 2ml of water, each 0.1ml you draw contains 0.5mg of semaglutide, on paper. In practice, powder that has degraded, clumped, or been inaccurately weighed means the concentration in any given draw could be higher or lower. Semaglutide's therapeutic doses in licensed products range from 0.25mg up to 2.4mg weekly, escalating slowly because the gastrointestinal side-effect burden rises sharply with dose. An accidental overdose is not a minor inconvenience.
Storage adds a third layer. Licensed Wegovy pens are kept refrigerated and carry a validated room-temperature stability window described in the Patient Information Leaflet. Reconstituted peptide solutions have no MHRA-validated stability data; potency and sterility both degrade, but the rate is uncharacterised for a given vial. You can read what a licensed semaglutide product actually involves on the NHS semaglutide information page.
If you are currently on a licensed product and want to understand the full Wegovy dose schedule, that information is covered in detail alongside what each step in the titration is designed to do.
Wegovy (semaglutide) is licensed in the UK for adults with a BMI of 30 or above, or 27 and above where a weight-related health condition is present. It is a prescription-only medicine. That means a prescriber must assess you before it can be dispensed, not because it is bureaucratic gatekeeping, but because semaglutide has genuine contraindications and interactions that vary by individual. The consultation is where those are caught.
The pen arrives pre-filled. No mixing. No bacteriostatic water. No concentration calculations. You inject once a week, rotating sites between the abdomen, thigh, and upper arm. The titration schedule starts low and increases in staged steps, which is why the semaglutide dosage chart people often look for relates to the weekly injection volume rather than a mixed concentration.
Private pricing is a genuine concern. Wegovy 10mg, the highest maintenance dose in the licensed titration, reflects how far the programme has come since launch, and its cost through private pharmacies has risen since Eli Lilly raised UK list prices in autumn 2025, and semaglutide has followed market dynamics. The UK Wegovy cost page covers what a realistic private prescription includes and what headline prices often leave out. Worth reading before drawing a conclusion about which route is genuinely cheaper when risk is factored in.
For a broader picture of what licensed weight-loss treatment involves in the UK, the weight-loss treatment overview sets out the options and the process clearly.
The decision you are actually making is not really about mixing ratios. It is about which route to weight loss is safe enough, regulated enough, and affordable enough to trust. Some people arrive at this question after months on a waiting list for NHS treatment, or after seeing a licensed product's price and flinching. Those are understandable positions.
What changes the calculation is the full picture of what an unlicensed reconstituted peptide involves: unverified purity, no clinical oversight, no prescriber to contact if something goes wrong, and no legal protection if the product harms you. A licensed private prescription through a GPhC-registered pharmacy is not the same as the NHS, but it is not the grey market either. Your consultation is reviewed by a real clinician, your supply comes through a regulated UK chain, and there is someone to call if you have a concern. You can learn more about the clinical team behind our prescribing on the clinical team page.
If you are curious about what Wegovy is as a licensed product, or want to understand the newly approved higher-dose options, both are covered in detail. And if you have a specific question about whether you would be eligible, the right starting point is a consultation rather than a forum thread. Check your eligibility with our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.